BTG plc acquires Novate Medical Ltd.

BTG plc (LSE: BTG), the global specialist healthcare company, today announces it has acquired Novate Medical Ltd. (“Novate”), a medical device company focused on the prevention of pulmonary embolism (PE) in patients at high risk of venous thromboembolic events.

Novate has developed Sentry, the first bioconvertible inferior vena cava (IVC) filter, which has recently been granted 510(k) regulatory clearance in the US. Sentry’s 12 month clinical trial data demonstrated no new symptomatic PE and no evidence of device migration, tilt, fracture, perforation or embolization, complications which have been associated with some other IVC filters. The unique bioconversion feature eliminates the need for an additional interventional procedure to retrieve the device.

BTG plans to launch Sentry in the US in the second half of FY2018/19 and will sell the device through its existing vascular sales force.

“This bolt-on acquisition further enhances BTG’s strength in the vascular space,” said Louise Makin, BTG’s CEO. “Novate’s unique IVC filter offers our existing customers a highly complementary product in the management of PE.”

BTG paid $20m in cash to acquire Novate and may be required to pay additional cash considerations up to $130m if certain commercial and sales-related milestones are met. The transaction is expected to be accretive to adjusted EPS from the second full year of ownership.

About BTG

BTG is a global healthcare company focused on Interventional Medicine. Our innovative medical technology helps physicians treat their patients through minimally invasive procedures. We have a growing portfolio of products that advance the treatment of cancer, vascular conditions and severe emphysema. BTG’s Pharmaceuticals business provides products that help patients overexposed to certain medications or toxins. To learn more about BTG, please visit: btgplc.com.

About Novate

Novate is a medical device company, incorporated in the Republic of Ireland, focused on the prevention of pulmonary embolism in patients at high risk of venous thromboembolic events. Novate had gross assets of EUR 3.6m at 31 December 2017, and incurred operating losses of EUR 2.0m for the year ended 31 December 2017.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180907005320/en/

BTGAndy Burrows, VP Corporate & Investor Relations+44 (0)20 7575 1741; Mobile: [phone]orStuart Hunt, Investor Relations Manager+44 (0)20 7575 1582; Mobile: [phone]orChris Sampson, Corporate Communications Director+44 (0)20 7575 1595; Mobile: [phone]orFTI ConsultingBen Atwell/Simon Conway+44 (0)20 3727 1000